Literature DB >> 8991632

Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome.

S Stöve1, T Welte, T O Wagner, A Kola, A Klos, W Bautsch, J Köhl.   

Abstract

The systemic inflammatory response of the body to invading microorganisms, termed sepsis, leads to profound activation of the complement system. Pathophysiological concepts suggest that complement activation occurs very early in this syndrome. Thus, we discuss whether the determination of concentrations of the complement components C3a, C5a, and C3 in plasma as well as of the C3a/C3 ratio might be helpful to diagnose sepsis early. For this purpose, 33 patients from an intensive care unit were monitored for 10 days. In comparison with healthy donors, C3a levels and the C3a/C3 ratio of intensive-care-unit patients were significantly elevated (P < 0.0001) on admission. In contrast, C3 levels were significantly reduced (P < 0.0001) but increased during the study. C5a levels in the plasma of healthy donors and patients were identical. Twenty-two of 33 patients fulfilled microbiological and clinical criteria of sepsis. Eleven patients had signs of systemic inflammatory response syndrome but no microbiological evidence of sepsis. The groups could be differentiated from each other by their C3a levels or their C3a/C3 ratios during the first 24 h after the clinical onset of sepsis (P < 0.05). Septic patients in shock had higher C3a levels than normotensive septic patients, although the differences were not significant. Nonsurvivors had significantly higher C3a levels on admission than survivors (P = 0.0185). No differences were found between septic patients who developed adult respiratory distress syndrome and those who did not. Thus, determination of C3a concentrations in plasma may prove useful (i) to diagnose sepsis early, (ii) to differentiate between patients with sepsis and those with systemic inflammatory response syndrome, and (iii) to assess prognosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8991632      PMCID: PMC170271          DOI: 10.1128/cdli.3.2.175-183.1996

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  42 in total

1.  Complement activation in septic shock patients.

Authors:  C L Sprung; D R Schultz; E Marcial; P V Caralis; M A Gelbard; P I Arnold; W M Long
Journal:  Crit Care Med       Date:  1986-06       Impact factor: 7.598

2.  Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions.

Authors:  H N Fernandez; P M Henson; A Otani; T E Hugli
Journal:  J Immunol       Date:  1978-01       Impact factor: 5.422

3.  Microvascular effects of anaphylatoxins C3a and C5a.

Authors:  J Björk; T E Hugli; G Smedegård
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

4.  Anaphylatoxin generation in multisystem organ failure.

Authors:  M Heideman; T E Hugli
Journal:  J Trauma       Date:  1984-12

5.  Biologically active products of complement and acute lung injury in patients with the sepsis syndrome.

Authors:  P F Weinberg; M A Matthay; R O Webster; K V Roskos; I M Goldstein; J F Murray
Journal:  Am Rev Respir Dis       Date:  1984-11

6.  Complement activation in patients at risk of developing the adult respiratory distress syndrome.

Authors:  J Duchateau; M Haas; H Schreyen; L Radoux; I Sprangers; F X Noel; M Braun; M Lamy
Journal:  Am Rev Respir Dis       Date:  1984-12

7.  Release of histamine from rat mast cells by the complement peptides C3a and C5a.

Authors:  A R Johnson; T E Hugli; H J Müller-Eberhard
Journal:  Immunology       Date:  1975-06       Impact factor: 7.397

8.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.

Authors:  B Beutler; I W Milsark; A C Cerami
Journal:  Science       Date:  1985-08-30       Impact factor: 47.728

Review 9.  Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients.

Authors:  B E Kreger; D E Craven; W R McCabe
Journal:  Am J Med       Date:  1980-03       Impact factor: 4.965

10.  Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates.

Authors:  J H Stevens; P O'Hanley; J M Shapiro; F G Mihm; P S Satoh; J A Collins; T A Raffin
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

View more
  20 in total

1.  Activation of the complement system generates antibacterial peptides.

Authors:  Emma Andersson Nordahl; Victoria Rydengård; Patrik Nyberg; D Patric Nitsche; Matthias Mörgelin; Martin Malmsten; Lars Björck; Artur Schmidtchen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-18       Impact factor: 11.205

Review 2.  The role of the anaphylatoxins in health and disease.

Authors:  Andreas Klos; Andrea J Tenner; Kay-Ole Johswich; Rahasson R Ager; Edimara S Reis; Jörg Köhl
Journal:  Mol Immunol       Date:  2009-05-28       Impact factor: 4.407

Review 3.  Sepsis, apoptosis and complement.

Authors:  P A Ward
Journal:  Biochem Pharmacol       Date:  2008-09-20       Impact factor: 5.858

4.  Functions of the complement components C3 and C5 during sepsis.

Authors:  Michael A Flierl; Daniel Rittirsch; Brian A Nadeau; Danielle E Day; Firas S Zetoune; J Vidya Sarma; Markus S Huber-Lang; Peter A Ward
Journal:  FASEB J       Date:  2008-06-27       Impact factor: 5.191

Review 5.  Biomarkers for the differentiation of sepsis and SIRS: the need for the standardisation of diagnostic studies.

Authors:  T C Hall; D K Bilku; D Al-Leswas; C Horst; A R Dennison
Journal:  Ir J Med Sci       Date:  2011-07-30       Impact factor: 1.568

6.  Complement activation is involved in biological responses to leukocyte adsorptive apheresis.

Authors:  Shoichi Nishise; Yuji Takeda; Hiroaki Takeda; Katsuyoshi Ishihama; Tadahisa Fukui; Sumio Kawata
Journal:  Dig Dis Sci       Date:  2006-04-27       Impact factor: 3.199

7.  Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization.

Authors:  Selene Nunez-Cruz; Phyllis A Gimotty; Matthew W Guerra; Denise C Connolly; You-Qiang Wu; Robert A DeAngelis; John D Lambris; George Coukos; Nathalie Scholler
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

Review 8.  Sepsis biomarkers: a review.

Authors:  Charalampos Pierrakos; Jean-Louis Vincent
Journal:  Crit Care       Date:  2010-02-09       Impact factor: 9.097

9.  Complement promotes the development of inflammatory T-helper 17 cells through synergistic interaction with Toll-like receptor signaling and interleukin-6 production.

Authors:  Chongyun Fang; Xinhua Zhang; Takashi Miwa; Wen-Chao Song
Journal:  Blood       Date:  2009-06-02       Impact factor: 22.113

10.  Inhibition of complement C5a prevents breakdown of the blood-brain barrier and pituitary dysfunction in experimental sepsis.

Authors:  Michael A Flierl; Philip F Stahel; Daniel Rittirsch; Markus Huber-Lang; Andreas D Niederbichler; L Marco Hoesel; Basel M Touban; Steven J Morgan; Wade R Smith; Peter A Ward; Kyros Ipaktchi
Journal:  Crit Care       Date:  2009-02-06       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.